货号:A465015
同义名:
Fluprostenol isopropyl ester;AL6221
Travoprost是一种合成前列腺素F2α类药物,作为强效选择性的FP前列腺素受体激动剂,用于控制青光眼或眼内高压的进展,方法是通过降低眼内压力。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Prostaglandin (PG) F(2α) is widely distributed in various organs and exhibits various biological functions, such as luteolysis, parturition, aqueous humor homeostasis, vasoconstriction, rennin secretion, pulmonary fibrosis[3]. Travoprost, a highly selective and potent analogue of the prostaglandin PGF(2α), has recently been approved and marketed as a topical ocular hypotensive agent for the treatment of ocular hypertension and glaucoma [4]. Travoprost produces a lower incidence of ocular irritation than PGF20 isopropyl ester at a dose of 1 μg in the New Zealand albino (NZA) rabbit. Topical ocular application of Travoprost produces a marked miotic effect in cats following doses of 0. 01, 0. 03 and 0.1 μg. In the ocular hypertensive monkey, b.i.d. application of 0.1 and 0.3 μg of travoprost afforded peak reduction in intraocular pressure (IOP) of 22.7% and 28.6%, respectively. Topical application of travoprost was well tolerated in rabbits, cats and monkeys, causing no ocular irritation or discomfort at doses up to 1 μg[5]. As assessed with YO-PRO-1 and Hoechst 33342 relative to cell viability determined with NR or AB, travoprost/timolol PQ produced significantly less apoptosis than travoprost/timolol BAK and latanoprost/timolol BAK and their respective BAK concentrations alone (P<0. 0001 for all) [6]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00767481 | Glaucoma Ocul... 展开 >>ar Hypertension 收起 << | Phase 3 | Terminated(Project Cancelled) | - | Mexico ... 展开 >> Mexico City, Mexico, 6700 收起 << |
NCT01253902 | Glaucoma, Open-Angle ... 展开 >> Ocular Hypertension 收起 << | Phase 4 | Completed | - | United States, Arkansas ... 展开 >> Rogers, Arkansas, United States Canada, Alberta Calgary, Alberta, Canada 收起 << |
NCT01253902 | - | Completed | - | - | |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.00mL 0.40mL 0.20mL |
9.99mL 2.00mL 1.00mL |
19.98mL 4.00mL 2.00mL |
CAS号 | 157283-68-6 |
分子式 | C26H35F3O6 |
分子量 | 500.548 |
别名 | Fluprostenol isopropyl ester;AL6221;Travoprost, AL-6221, Travatan, Travoprostin;Travoprostum;Flu-Ipr |
运输 | 蓝冰 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 |
溶解方案 |
DMSO: 40 mg/mL(79.91 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 无水乙醇: 60 mg/mL(119.87 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
动物实验配方 |